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Abstract
Background: Basal cell carcinoma (BCC) tumors are the most common skin cancer and are highly immunogenic.
Objective: The goal of this study was to assess how immune-cell related gene expression in an initial BCC tumor biopsy was
related to the appearance of subsequent BCC tumors.
Materials and Methods: Levels of mRNA for CD3e (a T-cell receptor marker), CD25 (the alpha chain of the interleukin (IL)-2
receptor expressed on activated T-cells and B-cells), CD68 (a marker for monocytes/macrophages), the cell surface
glycoprotein intercellular adhesion molecule-1 (ICAM-1), the cytokine interferon-c (IFN-c) and the anti-inflammatory
cytokine IL-10 were measured in BCC tumor biopsies from 138 patients using real-time PCR.
Results: The median follow-up was 26.6 months, and 61% of subjects were free of new BCCs two years post-initial biopsy.
Patients with low CD3e CD25, CD68, and ICAM-1 mRNA levels had significantly shorter times before new tumors were
detected (p = 0.03, p = 0.02, p = 0.003, and p= 0.08, respectively). Furthermore, older age diminished the association of
mRNA levels with the appearance of subsequent tumors.
Conclusions: Our results show that levels of CD3e, CD25, CD68, and ICAM-1 mRNA in BCC biopsies may predict risk for new
BCC tumors.
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Introduction
In 2006, more than 2 million individuals in the United States
were treated for non-melanoma skin cancers, mostly basal cell
carcinomas (BCC) [1,2]. Studies have linked a number of risk
factors to onset of BCCs, including male gender, fair skin that
burns easily and tans poorly, red or blond hair, blue eyes, Celtic
ancestry, proximity to the equator, older age, occupations that
involve sun or arsenic exposure, cumulative benign sun-related
skin damage, and sunburns before the age of 18 [3]. Indeed, sun
exposure during childhood may be particularly important in
determining risk [4]. The factors influencing the risk for additional
primary BCCs after the first are not completely clear.
There is good evidence that BCC is an immunogenic tumor.
For example, patients who are immunosuppressed following organ
transplantation have a substantially elevated risk for new BCCs, as
well as squamous cell carcinoma [5,6,7,8]. Comparisons of BCC
patients with sociodemographically-matched controls show poorer
immune responses among the former, including poorer prolifer-
ative responses to the mitogens concanavalin A (Con A) and
phytohemagglutinin (PHA), as well as decreased responsiveness of
T-cells to antigens, such as Candida. Furthermore, BCC tumors
that regress are characterized by greater lymphocyte trafficking to
the tumor and the surrounding stroma compared to tumors that
do not regress [9,10,11,12]. In one study the authors compared the
cells trafficking to regressing and non-regressing BCCs and found
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that regressing BCCs had a large number of CD4+ T
lymphocytes, but not CD8+ lymphocytes. In addition, the
numbers of interleukin (IL)-2 receptor positive T lymphocytes
and transferrin receptor-positive T lymphocytes were greater in
regressing tumors compared to those that were not regressing,
indicating that the T cells were activated [9,10]. Fifty percent of
tumors provide evidence of at least partial regression [10,13]. The
risk for development of subsequent primary BCCs after an initial
lesion is substantial, with 44% developing additional lesions within
3 years [14].
Further evidence for the critical role of the immune response in
BCC tumor development is the efficacy of imiquimod in the
treatment of this disease. This topical cream stimulates a local
immune response to BCC tumor cells. Imiquimod-induced
regression of BCC tumors was associated with increased
infiltration of inflammatory cells (within 3 to 5 days after initiation
of imiquimod treatment) concomitant with enhanced expression of
the intercellular adhesion molecule (ICAM)-1 [15]. Furthermore,
comparisons of the inflammatory infiltrates of BCC tumors pre-
and post-imiquimod treatment have shown that the predominant
infiltrating inflammatory cells were CD3+ and CD8+ T-cells,
although CD68+ cells (macrophages) also increased [16]. These
data are in accord with studies of regressing BCCs that showed
elevated levels of interferon gamma (IFN-c), IL-2 (a T-cell
marker), and CD3e (a T-cell cell surface marker) as measured
by RT-PCR, indicating an enhanced antitumor Th1 immune
response[10]. Thus, the expression of several immune-related
markers has been implicated in BCC progression [11,12]; and we
based our selection of markers on these studies. We measured
CD3e, IFN-c, CD25, CD68, ICAM-1 and IL-10 mRNA
expressed in BCC tumors to assess the relationship between the
expression of these genes (as measured by real time PCR) and the
occurrence of subsequent BCC tumors.
Materials and Methods
Participants
The BCC patient pathology results were obtained from
dermatology outpatient clinics affiliated with the Ohio State
University Medical Center. The final 138 BCC patients in our
study were screened for immunosuppressive disorders and
immunosuppressive drugs. They were not on medications that
would have promoted skin cancer. For those cases with tissue
samples of usable size, patient electronic medical records were
used to exclude individuals with immunosuppressive therapies,
immunological treatments for other medical conditions, another
cancer diagnosed within the last five years (except for a prior
BCC), or any history of SCC or melanoma. Eligible patients
received a letter from their treating dermatologist describing the
study; those who responded were contacted by phone to verify
medical history and study eligibility. A total of 174 participants
met eligibility criteria and were enrolled in the study. Of these, 7
did not have sufficient mRNA, 27 did not provide follow-up data,
and 2 were missing both mRNA and follow-up data. This left an
analysis sample of 138 BCC patients. Subjects excluded from the
analysis did not differ significantly from included subjects on any
demographic or clinical characteristics. The Ohio State University
Biomedical Research Review Committee approved the project; all
subjects gave written informed consent prior to participation.
Follow-up and endpoints
Patients were mailed questionnaires every six months for a
maximum of three years after the biopsy date of the BCC tumor
used in study analyses. The median follow-up was 26.6 months
[17]. At each assessment point, patients reported the month and
year of any new BCC removals that had occurred within the
previous six months. They also indicated whether or not they had
any other type of skin cancer, and they listed any changes in their
medical condition or current medications. Follow-up BCC
pathology data were also verified through the OSU Medical
Center electronic medical records both to validate patient self-
report data and identify any additional BCC tumors not reported
by patients. BCC tumor-free time period was defined as the time
from the biopsy date of the BCC tumor to the appearance of the
first subsequent new primary BCC tumor. The censoring date for
participants free of new tumors was the last contact date.
RNA extraction and cDNA synthesis
Four sections (10 mm thick each) were obtained from each of the
biopsies. The sections included tumor and surrounding area that
included some normal skin, dermis and lymphocytic infiltrate. The
paraffin-embedded diagnostic biopsies were combined in an
Eppendorf tube and immediately deparaffinized with xylene
followed by hydration through graded ethanol washes. After the
pathology lab prepared the four sections an additional section was
obtained in order to confirm that the four tissue sections were still
positive for tumor tissue. The tissue was then centrifuged and
digested with 100 ml digestion buffer (0.01 M Tris pH7.8,
0.005 M EDTA, and 0.5% SDS) plus 100 ml of 20 mg/ml
proteinase K for 24 hours at 55uC with agitation. Total RNA was
extracted by adding 800 ml Trizol Reagent (Life Technologies)
with 200 mg/ml glycogen as a carrier. Total RNA was precipitated
with 650 ml of 100% isoproponol at –40uC overnight then
centrifuged at maximum speed at room temperature. The pellets
were washed twice with 75% ice-cold ethanol. The RNA pellet
was resuspended in nuclease-free H2O, and quantified using a
Nanodrop spectrophotometer. Total RNA (1 mg) was treated with
DNase I (Life Technologies), followed by cDNA synthesis using
Superscript III RNase H- reverse transcriptase (Life Technologies).
cDNA was stored at 280uC until used for real-time PCR.
Gene Expression Studies, Real-time PCR and Data
Analysis
TaqMan Gene Expression Assays (Applied Biosystems) were
used for both internal positive controls and the genes of interest.
Using the Taqman Human Endogenous Control Plates (Applied
Biosystems) and the GeNorm software (http://medgen.ugent.be/
j˜vdesomp/genorm/) we selected the following as the appropriate
internal positive controls for this study: GAPDH (glyceraldehydes-
3-phosphate-dehydrogenase; Assay ID: 4326317E) and RPLP0
(large ribosomal protein; Assay ID 4326314E). The levels of
expression of CD3e (Assay ID: Hs99999153_m1), CD25 (Assay
ID: 4328847F), CD68 (Assay ID: Hs00154355_m1), ICAM-1
(Assay ID: Hs99999152_m1), IFN-c (Assay ID: Hs99999041_m1)
and IL-10 (Assay ID: Hs99999035_m1) mRNAs were normalized
to the geometric average of the CTs for GAPDH and RPLP0.
TaqMan Gene Expression Assay Reagents do not detect genomic
DNA sequences; therefore, these are specific to mRNA. mRNA
levels between samples were compared using relative real-time
RT-PCR with TaqMan fluorogenic probes, TaqMan PCR
Reagent Kit and 7300 Real-Time PCR System (Applied
Biosystems). We also included one sample in all of the PCR runs
to serve as our positive plate control. All genes of interest were first
normalized to the internal positive control, then normalized to the
positive plate control, and the relative expression of mRNA species
was calculated using the comparative CT method as described by
the manufacturer (see User bulletin #2 Applied Biosystems, P/N
4303859, 1997) [18].
Immune Risk Markers for BCC
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Statistical Methods
Univariate linear regression analyses and ANOVA models
were used to determine whether mRNA variables (log-
transformed) were significantly associated with demographic
and clinical characteristics. Kaplan-Meier plots and Cox
proportional hazards were used for survival analyses. The
proportional hazards assumption was checked for all predictive
factors for the Cox models, and, when the assumption was
found to have failed, interactions with time were incorporated to
address the nonproportional hazards. Initially, univariate
analyses examining the effect of mRNA variables on tumor-
free time period were performed, using a cutpoint of the median
observed value for each marker. Multivariate analyses were
performed, controlling for age and gender, as well as significant
interactions. We conducted parallel analyses using the log-
transformed mRNA markers values; resulting conclusions were
similar and are not shown. Alpha was set to 0.05, and two-sided
tests were conducted. All analyses were performed using SAS
version 9.1.
Results
Patient characteristics
Demographic and clinical characteristics of the 138 subjects
who had sufficient mRNA and follow-up data are summarized in
Table 1. The average age was 57.9 years (SD=13.2, range = 23–
92. Forty-eight subjects had nodular BCC, 35 had superficial
BCC, and the remaining 55 had mixed tumors. Half of the
subjects had tumors removed from the head and neck area
(n = 69). Sun exposure and sunburn history varied widely and is
summarized in Table 1 and Table S1.
Questions from the Older Adults Resources Survey (OARS)
Multidimensional Functional Assessment Questionnaire provided
data on the frequency of chronic conditions in the study
population [19] . Among the final 138 participants, the following
comorbid conditions were reported either at baseline or during
follow-up periods: arthritis, n = 15 (11%), asthma n= 6 (4%),
diabetes, n = 3 (2%), emphysema, n= 2 (1%), heart disease, n = 21
(15%), hypertension, n= 61 (44%), kidney disease, n = 2 (1%), liver
disease, n = 1 (1%), stroke, n= 7 (5%) and thyroid disease, n = 9
(7%).
Association between mRNA markers and patient
characteristics
CD3e, CD25, and ICAM-1 mRNA levels in tumor biopsies
showed a significant correlation with histological tumor type
(p = 0.003, p = 0.004, p = 0.03, respectively), with nodular
tumor type having lower levels of gene expression than the
superficial tumors or mixed tumors. Tumors removed from the
head and neck had lower levels of CD3e, CD25, ICAM-1, and
IFN-c mRNA compared to other sites (p = 0.002, p = 0.003,
p = 0.01, p = 0.03, respectively). Patients with a history of a
Table 1. Demographic and clinical characteristics of the
analysis sample (n = 138).
Characteristic
Demographics
Female sex, No. (%) 71 (51%)
White race, No. (%) 137 (99%)
Age (years), Mean (SD) 57.9 (13.2)
Age group (years), No. (%)
,30 3 (2%)
30–39 9 (7%)
40–49 21 (15%)
50–59 46 (33%)
60–69 38 (28%)
70–79 14 (10%)
80+ 7 (5%)
Education, No. (%)
High school or less 26 (19%)
Some college 79 (57%)
College degree 33 (24%)
Smoking status, No. (%)
Current 10 (7%)
Former 50 (36%)
Never 77 (56%)
Unknown 1 (1%)
Clinical Characteristics
BCC tumor type, No. (%)
Nodular 48 (35%)
Superficial 35 (25%)
Mixed type 55 (40%)
Had a prior BCC, No. (%) 111 (80%)
Number of BCC removed, No. (%)
Single 101 (73%)
Multiple 19 (14%)
Unknown 18 (13%)
BCC site, No. (%)
Head and neck 69 (50%)
Trunk 30 (22%)
Upper limbs 22 (16%)
Lower limbs 6 (4%)
Multi-site 7 (5%)
Unknown 4 (3%)
Sun exposure / Skin Type
Skin type - Burning
Always burn 15 (11%)
Usually burn 27 (20%)
Burn moderately 47 (34%)
Burn minimally 30 (22%)
Rarely/never burn 19 (14%)
Number of sunburns before age 19
0 11 (8%)
1–9 55 (40%)
Sun exposure / Skin Type
10–19 41 (30%)
20+ 30 (22%)
Unknown 1 (1%)
Additional sun exposure characteristics are available in Table S1.
doi:10.1371/journal.pone.0025160.t001
Table 1. Cont.
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prior BCC had significantly lower levels of CD3e, CD25,
CD68, and ICAM-1 mRNA (p = 0.01, p = 0.01, p = 0.005,
p = 0.03, respectively). There were no associations between
mRNA levels and the sun exposure variables. None of the
mRNA markers were significantly related to demographic
factors (age, gender, education level, smoking status). Though
the number of patients with comorbid conditions was small, we
did observe that patients with asthma (n = 6) had lower levels of
IL-10 mRNA (p = 0.05); there were no associations between
mRNA levels and other autoimmune related diseases (diabetes,
arthritis).
Associations among mRNA markers
Strong correlations existed among immune cell-associated
mRNA markers (Table 2). CD25, CD68, and ICAM-1 were all
highly positively correlated with CD3e (r.0.8 for all three
markers, p,0.0001). The strength of the association of IL-10
and IFN-c with CD3e was lower, r = 0.67 and r = 0.24
respectively, though still statistically significant (p,0.001 for both).
Thus, similar patterns of association with tumor-free periods
emerged for many immune cell markers, as described below.
Overall tumor-free time period and association with
patient demographics
Overall 61% of subjects were free of new BCCs at two years
post-initial biopsy (95% CI: 53%-70%). There was a borderline
effect of gender on risk for subsequent tumors; two years after the
initial biopsy 54% of males and 70% of females were free of new
BCCs (log-rank p= 0.12). There was a significant effect of age that
increased over time (p = 0.01), with older age increasing the risk of
a subsequent tumor. Therefore all adjusted models included
gender, age and an interaction between age and time. Patients
who had multiple BCCs removed had a marginally higher risk of a
subsequent tumor; at two years post-biopsy, 44% of subjects with
multiple BCCs removed were free of subsequent tumors compared
to 65% of subjects with a single BCC removed (log-rank p= 0.08).
Neither type of BCC tumor nor history of prior BCC tumors was
significantly associated with time to subsequent tumor (log-rank
p= 0.61, p = 0.59, respectively). No other demographic or sun
exposure variables listed in Table 1 were significantly associated
with time to subsequent BCCs.
Univariate survival analyses using median cutpoints for immune
cell markers revealed that patients with low CD3e mRNA levels in
their tumor biopsies had significantly shorter tumor-free time
periods (p = 0.03, Figure 1). Patients with low CD25 mRNA levels
also had significantly shorter tumor-free periods (p = 0.02,
Figure 2). There was no significant association between IFN-c
levels and time until subsequent tumors (p = 0.21). Adjusted
analyses revealed that older age dampened the effect of low levels
of CD3e and CD25 cells on time to subsequent tumors (Table 3).
The estimated relative risk of subsequent new tumors for low
versus high CD3e cells was 2.6 for subjects aged 50 at initial BCC
removal (p = 0.01), but this hazard ratio declined to 1.8 (p = 0.04)
for subjects aged 60 and 1.2 (p = 0.53) for subjects aged 70.
Similarly, the hazard ratio for low compared to high CD25 was
Table 2. Correlations (n) between pairs of mRNA markers.
CD25 CD68 ICAM-1 IFN-c IL-10
CD3e 0.92 0.84 0.80 0.24 0.67
(136) (136) (135) (136) (79)
CD25 0.88 0.84 0.17 0.75
(136) (135) (136) (79)
CD68 0.81 0.09 0.77
(136) (137) (79)
ICAM-1 0.13 0.77
(136) (79)
IFN-c 0.24
(79)
P-values,0.05 in bold. All mRNA values are log-transformed.
doi:10.1371/journal.pone.0025160.t002
Figure 1. Kaplan-Meier curves showing tumor-free time period for patients with CD3e mRNA levels $and,0.27 (the median CD3e
value).
doi:10.1371/journal.pone.0025160.g001
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higher for younger ages but declined to nonsignificance by age 70
(Table 3).
Without adjusting for age or gender, analyses showed that
patients with low CD68 mRNA expression in biopsies had
significantly shorter tumor-free periods (p = 0.003, Figure 3). In
adjusted models (Table 3) the effect of CD68 was modified by age,
similar to CD3e and CD25. The risk of recurrence for low versus
high CD68 was high for younger subjects (e.g., HR=3.9,
p = 0.004 for a subject aged 50) but declined with increasing
subject age (e.g., HR=21.1, p = 0.84 for a subject aged 70).
Low ICAM-1 mRNA levels in tumor biopsies had a borderline
association with shorter tumor-free periods (p = 0.08). In adjusted
models (Table 3), only at younger ages was the effect of low
ICAM-1 mRNA levels significant as older age decreased the
effect of the biomarker. There were no significant adjusted or
unadjusted associations between IL-10 mRNA levels and the
appearance of subsequent tumors. However, only 79 of 138
patients had IL-10 mRNA measurements available, reducing the
power to detect an effect. Nonetheless, effects were in the same
direction as the other mRNA markers, with low IL-10 levels
associated with an increased risk of subsequent tumors (adjusted
HR=1.8, p = 0.12).
A composite score using the four significant mRNA markers
(CD3e, CD25, CD68, and ICAM-1 mRNA) was generated
(n = 135 who had all markers available). The score was equal to
the number of markers that were below the median observed
value (ranging from 0 to 4). Thirty-three percent of subjects
(n = 44) had a score of zero, indicating high expression of all four
markers. Another 34% (n= 46) had scores ranging from one to
three, indicating elevated expression of some but not all markers.
The final 33% of subjects (n = 45) had below-median levels of all
four markers. Univariate analyses using this composite score
(Figure 4) revealed that patients with a 0 score had a statistically
significantly longer tumor-free time period compared to subjects
with a score of 4 (HR= 0.40, p = 0.02) or a score of 1-3
(HR= 0.36, p = 0.008). There was no significant difference
between the recurrence-free time period of subjects with a score
of 4 compared to those with scores 1–3 (p = 0.75). Multivariate
analyses adjusting for age and gender showed results similar to
those of the individual markers with an interaction of age with
score (Table 3).
To investigate potential confounding, clinical characteristics
that were significantly associated with either mRNA levels or
subsequent BCC occurrence were added to the survival models
describing the effect of mRNA levels. Controlling for these
characteristics did not substantially change point estimates or
change overall conclusions. In addition, all such variables were not
significant in the adjusted models and thus were left out of the final
presentation of results.
Discussion
Patients who have had a previous BCC are at increased risk for
new primary BCCs [14]. Our study investigated the expression of
several immune-related biomarkers (i.e., CD3e, CD25, CD68,
ICAM-1, IFN-c, and IL-10) in the peri-tumoral milieu of BCC
tumors and their relationship to the appearance of subsequent new
BCCs. We found that lower levels of CD3e, CD25, CD68, and
ICAM-1 mRNA in BCC tumor biopsies at baseline predicted
subsequent BCCs.
Prior studies have characterized the BCC peri-tumoral milieu.
For example, Hunt and co-workers studied primary BCC tumors
with and without histologic evidence of active or past regression.
Regression was defined histologically as the disruption of the
normal outline of tumor islands accompanied by lymphocytic
infiltration penetrating and surrounding the tumor [13]. They
suggested that some BCC tumors induced immune responses that
could lead to evidence of tumor disruption. In addition, they found
a significant increase in CD3 (a measure of total T cells) in actively
regressing tumors compared with those showing no regression.
Finally, expression of CD25 (IL-2 receptor) was greater in the
actively regressing BCC tumors compared with tumors that
showed no evidence of current or past regression. Consistent with
their data, we found that lower CD3e and CD25 mRNA levels in
BCC tumors were associated with increased risk for developing
subsequent BCCs.
Figure 2. Kaplan-Meier curves showing tumor-free time period for patients with CD25 mRNA levels $and,40.4 (the median CD25
value).
doi:10.1371/journal.pone.0025160.g002
Immune Risk Markers for BCC
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In addition, Wong and co-workers described the cytokine
profiles of BCC tumors showing histologic regression [10]. They
noted a trend towards higher CD3 and IL-2 mRNA levels in
actively regressing tumors. Furthermore, IFN-cmRNA levels were
strongly correlated with levels of CD3 mRNA, which was
interpreted as evidence for activated lymphocytes producing a
Th1 type immune response in actively regressing BCC tumors.
However, in contrast to their observation we did not observe an
association between IFN-c mRNA levels and risk for subsequent
tumors.
Increased expression of ICAM-1, the ligand for lymphocyte
function-associated antigen-1 (LFA-1) on both T- and B-
lymphocytes, is one effect of IFN-c that is linked to anti-tumor
properties. For example, imiquimod-induced regression of BCC
tumors was associated with increased infiltration of inflammatory
cells (within 3 to 5 days after initiation of imiquimod treatment)
concomitant with enhanced expression of ICAM-1 [15]. Another
study showed that daily treatment of 12 BCCs in 11 patients with
5% imiquimod cream at night for at least 8 h five times per week
resulted in the greater influx of inflammatory cells (primarily
CD45+ lymphocytes and CD68+ macrophages) in the tumor
biopsies compared to biopsies collected before treatment [16]. We
found that lower levels of ICAM-1 mRNA were associated with an
increased risk of subsequent BCCs. Lower levels of ICAM-1
mRNA could also reflect lower infiltration of inflammatory cells
which could enhance risk for subsequent tumors. Our study
demonstrated an association between CD3e, CD25, CD68, and
ICAM-1 mRNA levels in BCC tumor biopsies and the risk for
subsequent tumors. These results support an important role for
inflammatory cells in the peri-tumoral milieu and for immune cells
that infiltrate BCC tumors and thus mediate BCC tumor
progression [12,13,20].
It is interesting to note that we did not observe a significant
association between IL-10 mRNA levels and the appearance of
subsequent tumors but the trend is as seen with the other markers.
Besides being produced by T-cells, B-cells, and monocytes, IL-10
has been shown to be produced by BCC tumor cells as well
[11,21]. This lack of association may be explained by the fact that
the methodology used here can detect IL-10 mRNA from both
infiltrating immune cells and the BCC tumor cells. The association
Table 3. Tumor-free time period: Hazard ratios (HR) for low versus high levels of immune markers.
Models{ Unadjusted model Adjusted
Model N Comparison HR 95% CI p-value Age* HR 95% CI p-value
CD3e 136 low vs. high 1.9 1.1–3.2 0.03 50 2.6 1.2–5.7 0.01
60 1.8 1.03–3.2 0.04
70 1.2 0.63–2.4 0.53
Age x CD3e interaction p = 0.10
IFN-c 138 low vs. high 0.71 0.42–1.2 0.21 any 0.73 0.42–1.2 0.24
CD25 136 low vs. high 1.9 1.1–3.3 0.02 50 3.2 1.4–7.2 0.004
60 1.9 1.04–3.3 0.04
70 1.1 0.55–2.1 0.84
Age x CD25 interaction p = 0.02
CD68 137 low vs. high 2.3 1.3–4.2 0.004 50 3.9 1.7–8.7 0.001
60 2.3 1.29–4.2 0.005
70 1.4 0.70–2.8 0.34
Age x CD68 interaction p = 0.04
ICAM-1 136 low vs. high 1.6 0.94–2.8 0.08 50 2.3 1.1–4.9 0.04
60 1.6 0.91–2.8 0.11
70 1.1 0.57–2.2 0.75
Age x ICAM-1 interaction p = 0.12
IL-10 79 low vs. high 1.6 0.82–3.2 0.16 any 1.8 0.87–3.7 0.12
Score** 135 1–3 vs. 0 2.8 1.3–5.9 0.008 50 4.5 1.5–14 0.009
60 2.6 1.2–6 0.02
70 1.5 0.6–3.5 0.38
4 vs. 0 2.5 1.2–5.4 0.02 50 4.2 1.4–12.9 0.01
60 2.4 1.09–5.5 0.03
70 1.4 0.60–3.4 0.42
Separate Cox models for each biomarker.
{Adjusted for gender, age at initial BCC, interaction of age with time.
*Some models have an interaction of biomarker level (binary) with age at initial BCC removal (continuous variable), as shown above. When the interaction was present,
the effect of mRNA marker level is interpreted for a specific age.
**Combined score defined as the number of mRNA markers out of CD3e, CD25, CD68, and ICAM-1 that are below the median: 0 (none below) / 1–3 (some below) / 4 (all
below). P-value for age by score interactions are p = 0.07 and p = 0.08 for some vs. none and all vs. none, respectively.
Effects are presented separately for age 50, 60, and 70 where age moderated effects.
doi:10.1371/journal.pone.0025160.t003
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might have been stronger if we had been able to differentiate the
IL-10 mRNA expressed by immune cells from that made by the
tumor cells.
Animal models of BCC have demonstrated that BCC growth is
impacted by cell mediated, humoral mediated and NK mediated
inflammation [22]. Mechanistically, it would have been useful to
know if our immune markers were associated with the host
immune response as well as with risk of additional BCCs [12], a
limitation of this study and an important direction for future work.
In addition, future studies should also compare BCC edge mRNA
results with adjacent normal skin to support the contention that
the mRNA data are most likely due to the immune response and
not the circulating inflammatory cells.
The occurrence of BCC can also indicate other cancer risks:
individuals with a history of nonmalignant skin cancers are at
increased risk for death from a variety of noncutaneous cancers
[23,24,25,26]. For example, a large prospective study with over
one million participants found mortality over the next 12 years
from all noncutaneous cancers was 20 to 30 % higher among
individuals who reported no cancer at baseline (other than a
history of nonmalignant skin cancer) than among those who did
not share the same history; the relative risk for mortality from
Figure 3. Kaplan-Meier curves showing tumor-free time period for patients with CD68 mRNA levels$and ,1.49 (the median CD68
value).
doi:10.1371/journal.pone.0025160.g003
Figure 4. Kaplan-Meier curves showing tumor-free time period by composite mRNA marker score, defined as the number of mRNA
markers (CD3e, CD25, CD68, and ICAM-1) that are below the median.
doi:10.1371/journal.pone.0025160.g004
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other cancer was 1.30 in men and 1.26 in women [23]. Indeed,
skin cancer patients are at higher risk for second primary non-
cutaneous malignancies, often those related to smoking or
lymphoproliferative malignancies [24,25,26]. Thus, studying
factors associated with the BCC risk may also shed some light
on broader cancer risks.
Chronic ultraviolet radiation (UVR) exposure leads to the
accumulation of elastotic material [27], a potent immunosuppres-
sant [28] that stimulates local production of immunosuppressive
molecules [29], which can induce antigen-specific tolerance [30],
abrogating the effector phase of cell-mediated immunity [31]. The
acquisition of solar elastotic material also disrupts lymphatic
drainage, which may also play a role in decreased immunity [32].
We found that tumors removed from the head and neck expressed
lower levels of CD3e, CD25, ICAM-1, and IFN-c mRNA
compared to tumors from other sites. The expression of these
markers in tumors from less exposed parts of the body may be
related to chronic UVR exposure or deposition of elastotic
material.
In this study, we focused on a selection of immune cell markers
that have been related to the regression of BCC tumors in previous
studies. Recent studies have described the molecular mechanisms
involved in the initiation and progression of BCC. These
observations have implicated the hedgehog signaling pathway in
the molecular pathogenesis of BCC [33,34]. The pivotal roles of
signaling proteins including patched homolog 1 (PTCH-1) and
smoothened (SMO) are of great interest to us but this topic is
beyond the scope of this study [35]. Future studies could include
other immune cell markers such as IL-2 receptor positive cells,
dendritic cells and measures of the response of peripheral blood
leukocytes to Con A and PHA. Nevertheless, we believe that the
data obtained in this study may provide a useful approach for
identifying BCC patients at risk for subsequent tumors.
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